Sinovac Biotech, Net Income

The latest net income for SVA is $14M as of December 2023. That compares with $8.6B in the prior-year period — down 99.8% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Sinovac Biotech,'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SVA's net income moved from $8.6B to $14M — a 99.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sinovac Biotech,'s operating scale or balance-sheet position.

Against Healthcare companies, SVA currently prints $14M for net income, while the sector average sits near $16B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Sinovac Biotech,'s growth, margins, and balance sheet.

A net income figure of $14M for SVA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting SVA's net income ($14M), review year-over-year change from $8.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.